Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Theodosios D Filippatos & Moses S Elisaf. (2015) Safety considerations with fenofibrate/simvastatin combination. Expert Opinion on Drug Safety 14:9, pages 1481-1493.
Read now
Read now
Manfredi Rizzo, Giuseppe Montalto & Khalid Al-Rasadi. (2014) Treatment options for managing atherogenic dyslipidemia and fatty liver disease. Expert Opinion on Pharmacotherapy 15:8, pages 1065-1068.
Read now
Read now
Francisco Mesa, Antonio Magán-Fernández, Dragana Nikolic, Rafael Marfil-Alvarez, Luigi Nibali & Manfredi Rizzo. (2014) Periodontitis, blood lipids and lipoproteins. Clinical Lipidology 9:2, pages 261-276.
Read now
Read now
Manfredi Rizzo, Pablo Perez-Martinez, Dragana Nikolic, Giuseppe Montalto & Jose Lopez-Miranda. (2013) Emerging approaches for the treatment of hypertriglyceridemia. Expert Opinion on Pharmacotherapy 14:14, pages 1869-1873.
Read now
Read now
Manfredi Rizzo, Gerald H Tomkin, Maria Patti Angelo, Ilenia Pepe, Rosa Valerio Maria, Salvatore Di Rosa, Battista Rini Giovam & Gaetana D Fede. (2011) Effects of hypolipidemic and hypoglycemic agents on atherogenic small, dense LDL in Type 2 diabetes. Clinical Lipidology 6:5, pages 539-547.
Read now
Read now
Theodosios D Filippatos & Moses S Elisaf. (2011) Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia. Expert Opinion on Pharmacotherapy 12:12, pages 1945-1958.
Read now
Read now
Ilan Goldenberg, Michal Benderly & Uri Goldbourt. (2008) Update on the use of fibrates: focus on bezafibrate. Vascular Health and Risk Management 4:1, pages 131-141.
Read now
Read now
Articles from other publishers (15)
Tsutomu Hirano, Rieko Kodera, Takeshi Hirashima, Natsuko Suzuki, Ema Aoki, Mitsuru Hosoya, Taito Oshima, Toshiyuki Hayashi, Shinji Koba, Motoko OhtaNoriyuki SatohYasuki Ito. (2022) Metabolic Properties of Lowdensity Lipoprotein (LDL) Triglycerides in Patients with Type 2 Diabetes, Comparison with Small Dense LDL-Cholesterol. Journal of Atherosclerosis and Thrombosis 29:5, pages 762-774.
Crossref
Crossref
Ali A. RizviDragana NikolicHanaa S. SallamGiuseppe MontaltoManfredi RizzoNicola Abate. (2014) Adipokines and Lipoproteins: Modulation by Antihyperglycemic and Hypolipidemic Agents. Metabolic Syndrome and Related Disorders 12:1, pages 1-10.
Crossref
Crossref
莹 夏. (2014) The New Idea in the Synthesis of Lipid-Regulator Fibrates. Hans Journal of Medicinal Chemistry 02:04, pages 47-53.
Crossref
Crossref
Antonio M. GottoJr.Jr. & John A. Farmer. 2013. Essential Cardiology. Essential Cardiology
405
418
.
Theodosios D. Filippatos. (2012) A Review of Time Courses and Predictors of Lipid Changes with Fenofibric Acid-Statin Combination. Cardiovascular Drugs and Therapy 26:3, pages 245-255.
Crossref
Crossref
Yun-Jung Choi, Brian K. Roberts, Xueyan Wang, J. Casey Geaney, Sue Naim, Kathleen Wojnoonski, David B. Karpf & Ronald M. Krauss. (2012) Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia. Atherosclerosis 220:2, pages 470-476.
Crossref
Crossref
Harold E. BaysArvind ShahGeraldine MacdonellWilliam V. TaggartBarry Gumbiner. (2011) Effects of Coadministered Ezetimibe Plus Fenofibrate in Mixed Dyslipidemic Patients with Metabolic Syndrome. Metabolic Syndrome and Related Disorders 9:2, pages 135-142.
Crossref
Crossref
Kosmas I. ParaskevasAlkistis Pantopoulou, Ioannis S. Vlachos, George Agrogiannis, Dimitrios G. Iliopoulos, Gabriel Karatzas, Dimitrios Tzivras, Dimitri P. Mikhailidis & Despina N. Perrea. (2011) Comparison of Fibrate, Ezetimibe, Low- and High-Dose Statin Therapy for the Dyslipidemia of the Metabolic Syndrome in a Mouse Model. Angiology 62:2, pages 144-154.
Crossref
Crossref
K. Berneis, M. Rizzo, H. K. Berthold, G. A. Spinas, W. Krone & I. Gouni-Berthold. (2010) Ezetimibe alone or in combination with simvastatin increases small dense low-density lipoproteins in healthy men: a randomized trial. European Heart Journal 31:13, pages 1633-1639.
Crossref
Crossref
Manfredi Rizzo, Vincenzo Pernice, Arian Frasheri, Gabriele Di Lorenzo, Giovam Battista Rini, Giatgen A. Spinas & Kaspar Berneis. (2009) Small, dense low-density lipoproteins (LDL) are predictors of cardio- and cerebro-vascular events in subjects with the metabolic syndrome. Clinical Endocrinology 70:6, pages 870-875.
Crossref
Crossref
Manfredi Rizzo, Giovam Battista Rini, Giatgen A. Spinas & Kaspar Berneis. (2009) The effects of ezetimibe on LDL-cholesterol: Quantitative or qualitative changes?. Atherosclerosis 204:2, pages 330-333.
Crossref
Crossref
Manfredi Rizzo, Ali A. Rizvi, Giovam Battista Rini & Kaspar Berneis. (2008) The therapeutic modulation of atherogenic dyslipidemia and inflammatory markers in the metabolic syndrome: what is the clinical relevance?. Acta Diabetologica 46:1, pages 1-11.
Crossref
Crossref
Diane L. Tribble, Michel Farnier, Geraldine Macdonell, Inna Perevozskaya, Michael J. Davies, Barry Gumbiner & Thomas A. Musliner. (2008) Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia. Metabolism 57:6, pages 796-801.
Crossref
Crossref
Marco Fidaleo & Claudia Sartori. (2008) Administration of ciprofibrate to lactating mothers induces PPARα-signaling pathway in the liver and kidney of suckling rats. Experimental and Toxicologic Pathology 60:1, pages 33-41.
Crossref
Crossref
M. Rizzo & K. Berneis. (2007) Who needs to care about small, dense low-density lipoproteins?. International Journal of Clinical Practice 61:11, pages 1949-1956.
Crossref
Crossref